Treats non-central nervous system manifestations of alpha-mannosidosis. Sold as Lamzede. Every FDA application for this active ingredient. Orphan exclusivity to Feb 16, 2030
As of Nov 22, 2026, FDA lists 1 application for Velmanase alfa-tycv (sold as Lamzede), first approved Feb 16, 2023, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 16, 2023 | LamzedeBLA 761278 · New molecular entity | Chiesi Farmaceutici | 0 | Marketed |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Lamzede | Part B | $0 | −100% | 0 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA